🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to scientists.

An International Health Concern

Gonorrhoea infections are on the rise worldwide, with figures suggesting more than 82 million instances each year. Especially elevated rates are observed in the African continent and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Health officials are deeply concerned about the increase in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Experts hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to bring it to fruition.

“This approval represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Outcomes and Global Access

Based on data detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an equal footing with the current standard treatment, which uses a dual-drug approach. The study included over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have voiced hope. Having a one-pill regimen such as this is hailed as a "critical tool" for managing the epidemic. This is considered vital to alleviate the strain of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.